These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 26174114

  • 1. Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma.
    Yang S, Goyal N, Beerahee M, Trivedi R, Lee L, Pascoe S.
    Eur J Clin Pharmacol; 2015 Sep; 71(9):1051-8. PubMed ID: 26174114
    [Abstract] [Full Text] [Related]

  • 2. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study.
    Lee LA, Yang S, Kerwin E, Trivedi R, Edwards LD, Pascoe S.
    Respir Med; 2015 Jan; 109(1):54-62. PubMed ID: 25452139
    [Abstract] [Full Text] [Related]

  • 3. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
    Lee L, Kerwin E, Collison K, Nelsen L, Wu W, Yang S, Pascoe S.
    Respir Med; 2017 Oct; 131():148-157. PubMed ID: 28947022
    [Abstract] [Full Text] [Related]

  • 4. A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma.
    Lee LA, Briggs A, Edwards LD, Yang S, Pascoe S.
    Respir Med; 2015 Jan; 109(1):63-73. PubMed ID: 25464907
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A.
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [Abstract] [Full Text] [Related]

  • 6. A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids.
    Kerwin E, Pascoe S, Bailes Z, Nathan R, Bernstein D, Dahl R, von Maltzahn R, Robbins K, Fowler A, Lee L.
    Respir Res; 2020 Jun 12; 21(1):148. PubMed ID: 32532275
    [Abstract] [Full Text] [Related]

  • 7. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
    Sousa AR, Riley JH, Church A, Zhu CQ, Punekar YS, Fahy WA.
    NPJ Prim Care Respir Med; 2016 Jun 23; 26():16031. PubMed ID: 27334739
    [Abstract] [Full Text] [Related]

  • 8. Dose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studies.
    Donohue JF, Kalberg C, Shah P, Beerahee M, Mehta R, Gunawan R, Church A.
    J Clin Pharmacol; 2014 Nov 23; 54(11):1214-20. PubMed ID: 24895108
    [Abstract] [Full Text] [Related]

  • 9. A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers.
    Yang S, Lee L, Mallett S, Ayer J, Wolstenholme A, Pascoe S.
    Adv Ther; 2015 Feb 23; 32(2):157-71. PubMed ID: 25700806
    [Abstract] [Full Text] [Related]

  • 10. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids.
    Bleecker ER, Bateman ED, Busse WW, Woodcock A, Frith L, House KW, Jacques L, Davis AM, Haumann B, Lötvall J.
    Ann Allergy Asthma Immunol; 2012 Nov 23; 109(5):353-358.e4. PubMed ID: 23062392
    [Abstract] [Full Text] [Related]

  • 11. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.
    Bleecker ER, Lötvall J, O'Byrne PM, Woodcock A, Busse WW, Kerwin EM, Forth R, Medley HV, Nunn C, Jacques L, Bateman ED.
    J Allergy Clin Immunol Pract; 2014 Nov 23; 2(5):553-61. PubMed ID: 25213048
    [Abstract] [Full Text] [Related]

  • 12. Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma.
    Braithwaite I, Williams M, Power S, Pilcher J, Weatherall M, Baines A, Moynihan J, Kempsford R, Beasley R, FF/VI Study Team.
    Respir Med; 2016 Oct 23; 119():115-121. PubMed ID: 27692131
    [Abstract] [Full Text] [Related]

  • 13. Inhaled steroid/long-acting beta 2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients.
    Lötvall J, Langley S, Woodcock A.
    Respir Res; 2006 Aug 18; 7(1):110. PubMed ID: 16919161
    [Abstract] [Full Text] [Related]

  • 14. Population Pharmacokinetics Modeling of Inhaled Umeclidinium for Adult Patients with Asthma.
    Yang S, Lee L, Pascoe S.
    Eur J Drug Metab Pharmacokinet; 2017 Feb 18; 42(1):79-88. PubMed ID: 27026339
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A.
    Lancet Respir Med; 2014 Jun 18; 2(6):472-86. PubMed ID: 24835833
    [Abstract] [Full Text] [Related]

  • 16. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials.
    Donohue JF, Singh D, Munzu C, Kilbride S, Church A.
    Respir Med; 2016 Mar 18; 112():65-74. PubMed ID: 26797016
    [Abstract] [Full Text] [Related]

  • 17. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.
    Busse WW, Bleecker ER, Bateman ED, Lötvall J, Forth R, Davis AM, Jacques L, Haumann B, Woodcock A.
    Thorax; 2012 Jan 18; 67(1):35-41. PubMed ID: 21828231
    [Abstract] [Full Text] [Related]

  • 18. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Kelleher D, Tombs L, Preece A, Brealey N, Mehta R.
    Pulm Pharmacol Ther; 2014 Oct 18; 29(1):49-57. PubMed ID: 25020273
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A.
    Respir Med; 2013 Oct 18; 107(10):1538-46. PubMed ID: 23830094
    [Abstract] [Full Text] [Related]

  • 20. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome.
    Ishiura Y, Fujimura M, Shiba Y, Ohkura N, Hara J, Kasahara K.
    Pulm Pharmacol Ther; 2015 Dec 18; 35():28-33. PubMed ID: 26497109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.